Special thanks to Aaron Graham from Boehringer Ingelheim for being our guest yesterday on the Town Hall. Counterfeiting continues to grow worldwide, and it was great to hear about successful mitigation as well as what we all need to look out for in the future. Thank you to everyone who attended the Town Hall and offered their views. Don’t hesitate to reach out to me on future topics or speaker recommendations.
Please don’t forget about updates to and availability of Audit Reports that can be licensed through Rx-360. You can view our audit library at https://rx-360.org/licensable-audit-reports/ . For more information please contact Jaye Greene at [email protected].
Rx-360 has also become a leader in transitioning audit needs to the remote model, given the current pandemic. If you need information on sponsoring an audit through Rx-360, or would like more information on our remote audit capabilities, please reach out to Hannah Song at [email protected].
If you are interested in being part of the planning, or a speaker for an upcoming Rx-360 Virtual Conference on Supply Chain Integrity in the Africa Region, please contact Jim Fries for more details ([email protected]).
FDA Plans to Restart Facility Inspections: https://www.medtechdive.com/news/fda-cdc-drawing-up-plan-to-restart-routine-facility-inspections/577740/
Here is a link to a recent posting on the APEC website on Supply Chain Security during COVID-19. Please note that within the article is a link to the APEC Supply Chain Security Tollkit that many Rx-360 Members played a role in developing. http://apec.org/Press/Blogs/2020/0520_Supply
Pharmaceutical Onshoring Outlook in the Wake of COVID-19: https://blog.burnsmcd.com/the-outlook-for-pharmaceutical-onshoring-in-the-wake-of-covid-19?utm_campaign=GFS_2018_Manufacturing&utm_source=GFS_OnshoringUSPharmaceuticalSupplyChain_Elevate_Blog-OutlookforPharmaceuticalOnshoringinWakeofCOVID19_16442
Thank you again and please don’t hesitate to reach out if Rx-360 can be of any help to you or your organization during this time.